Special meeting of Impact Biomedical stockholders to approve the proposed Business Combination scheduled for November 13, 2026, at 10:00 a.m. Eastern Standard TimeUpon closing, the combined company is expected to
Special meeting of Impact Biomedical stockholders to approve the proposed Business Combination scheduled for November 13, 2026, at 10:00 a.m. Eastern Standard TimeUpon closing, the combined company is expected to
ROCHESTER, N.Y., Sept. 16, 2026 (GLOBE NEWSWIRE) -- DSS, Inc. (NYSE:DSS) ("DSS" or the "Company") today announced that Zoar Limited ("Zoar" or "PubCo") has filed a Registration
HOUSTON, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Impact Biomedical Inc. (NYSE:IBO) (the "Company" or "Impact") announced that a Form F-4 registration statement (the "Registration Statement") was
HOUSTON, Sept. 14, 2026 (GLOBE NEWSWIRE) -- This corrected press release is being issued to correct the merger exchange ratio that was incorrectly stated in the press release of Impact Biomedical Inc. (the
HOUSTON, Sept. 11, 2026 (GLOBE NEWSWIRE) -- Impact BioMedical Inc. (the "Company") today announced that the Company's Board of Directors has approved a 1 for 12.62 reverse stock split of the Company's
Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Impact Biomedical Inc. (NYSE:IBO) resulting from allegations that Impact
Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Impact Biomedical Inc. (NYSE:IBO) resulting from allegations that Impact
HOUSTON, April 03, 2026 (GLOBE NEWSWIRE) -- Impact BioMedical Inc. (NYSE:IBO) announced that its annual report(10-K) for the fiscal year ending December 31, 2025, filed on March 11, 2026, includes an audit opinion from
HOUSTON, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Impact Biomedical Inc. (IBO) is pleased to announce that the US Patent and Trademark Office has issued U.S. patent No. 12,357,584 B2 entitled "Composition and Method of
Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Impact BioMedical Inc. (NYSE:IBO) and Dr Ashleys Limited is fair to Impact shareholders.
Halper Sadeh encourages Impact
A Strategic Move to Accelerate Market Reach for Innovative Pharmaceutical Patents on June 23, 2025 NEW YORK, June 23, 2025 (GLOBE NEWSWIRE) -- Dr Ashleys Limited, a Hong Kong based global pharmaceutical company ("Dr
HOUSTON, March 21, 2025 (GLOBE NEWSWIRE) -- Impact BioMedical Inc. (NYSE:IBO), a pioneering biotechnology company dedicated to discovering, developing, and patenting innovative healthcare solutions, today announced
ROCHESTER, N.Y., Feb. 26, 2025 (GLOBE NEWSWIRE) -- DSS, Inc. (NYSE:DSS), a multinational company focused on innovation-driven business models, today announced the sale of its Celios® air purification asset to
HOUSTON, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Impact BioMedical Inc. (NYSE:IBO), a pioneering biotechnology company dedicated to discovering, developing, and patenting innovative healthcare solutions, today announced the
